SCHEMBL2312958

SCHEMBL2312958

O=C1NC(=O)c2c(CC=CBr)cccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.42
GSK3B P49841 3/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NPSR1 Q6W5P4 2/20 0.37
CASP7 P55210 2/20 0.36
MEN1 O00255 2/20 0.36
POLB P06746 2/20 0.36
KMT2A Q03164 2/20 0.36
RGS12 O14924 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
CYP2C9 P11712 1/20 0.36
APEX1 P27695 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16863190 0.90 PARP1 (0.47) PARP1GSK3BKDM4EALDH1A1GAA
SCHEMBL7348724 0.86 PARP1 (0.41) PARP1GSK3BKDM4EALDH1A1GAA
SCHEMBL11615870 0.84 KDM4E (0.42) PARP1GSK3BKDM4EALDH1A1GAA
SCHEMBL4975651 0.84 PARP1 (0.42) PARP1GSK3BKDM4EALDH1A1GAA
SCHEMBL10416488 0.84 PARP1 (0.42) PARP1GSK3BKDM4EALDH1A1GAA
SCHEMBL709378 0.81 GSK3B (0.43) PARP1GSK3BKDM4EALDH1A1GAA
SCHEMBL6347009 0.81 PARP1 (0.40) PARP1GSK3BKDM4EALDH1A1GAA
SCHEMBL28160075 0.80 MAOA (0.46) PARP1GSK3BKDM4EALDH1A1GAA
SCHEMBL10879460 0.80 PARP1 (0.39) PARP1GSK3BKDM4EALDH1A1GAA
SCHEMBL170914 0.80 GABRA1 (0.49) PARP1GSK3BKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113402448-B Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof 中国船舶重工集团公司第七二五研究所 2023-03-17 CN claimed
CN-113402448-A Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof 中国船舶重工集团公司第七二五研究所 2021-09-17 CN claimed
US-6657081-B1 Extraction of actinides and lanthanides from aqueous solutions COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2003-12-02 US claimed
CN-113402448-B Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof 中国船舶重工集团公司第七二五研究所 2023-03-17 CN disclosed
CN-113402448-B Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof 中国船舶重工集团公司第七二五研究所 2023-03-17 CN disclosed
CN-113402448-A Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof 中国船舶重工集团公司第七二五研究所 2021-09-17 CN disclosed
CN-113402448-A Terpyridyl primary amine organic corrosion inhibitor and preparation method and application thereof 中国船舶重工集团公司第七二五研究所 2021-09-17 CN disclosed
EP-3796900-A1 TRITERPENE AMINE DERIVATIVES DFH Therapeutics (US) 2021-03-31 EP disclosed
US-20130190407-A1 CALCIUM RECEPTOR-ACTIVE MOLECULES NPS PHARMACEUTICALS, INC. (US) 2013-07-25 US disclosed
US-7989451-B2 Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments AUCKLAND UNISERVICES LIMITED (NZ) 2011-08-02 US disclosed
EP-1866292-B1 TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS AUCKLAND UNISERVICES LTD (NZ) 2010-12-15 EP disclosed
US-5294715-A Acridine-intercalator based hypoxia selective cytotoxins UNIVERSITY OF PITTSBURGH (US) 1994-03-15 US disclosed
US-5264576-A Antiserotonin agents, antidepressants and obsessive-compulsive disorders HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-11-23 US disclosed
WO-1993004373-A1 CALCIUM RECEPTOR ACTIVE MOLECULES NPS PHARMACEUTICALS, INC. (US) 1993-03-04 WO disclosed
WO-1993000906-A1 MUSCARINIC ANTAGONISTS THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1993-01-21 WO disclosed
US-5021429-A Histamine h2-antagonists; antisecretory-antiallergen agent; skin disorders and peptic ulcers ALLEN & HANSBURYS LIMITED (GB) 1991-06-04 US disclosed
US-4613695-A ANTITUMOR AKTIEBOLAGET LEO (SE) 1986-09-23 US disclosed
EP-0194046-A1 Dihydropyridine alkanol amines, process for their preparation and pharmaceutical compositions containing them IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-09-10 EP disclosed
US-4568685-A THROMBOXANE SYNTHETASE ENZYME INHIBITORS, HYPOTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1986-02-04 US disclosed
US-4038412-A ANTI-VIRAL AGENTS RICHARDSON-MERRELL INC. (US) 1977-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190407-A1 CALCIUM RECEPTOR-ACTIVE MOLECULES CASR, CALCR, ORAI1 PARP1 2764/4885GSK3B 4383/4885KDM4E 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.